The $2.6bn acquisition of The Binding Site is 2022’s biggest medtech deal, but investors are unmoved.
The new variant might be able to dodge one of the PCR tests authorised in the US, the FDA says.
An evolving virus demands innovative diagnostic technologies.
And consolidation in the diagnostics space is only just beginning.
Medtronic’s quarterly results yesterday might presage a recovery, and some groups are in dire need of one.